UK – NICE backs Sandoz’ Rizmoic

The drug is an oral peripherally acting mu-opioid receptor antagonist (PAMORA), approved in Europe on the back of evidence showing that is increases the frequency of bowel movements compared with no treatment and other PAMORAs.

In two of studies, involving 1,095 patients taking opioids for chronic pain caused by a condition other than cancer, 50% of patients taking Rizmoic for 12 weeks achieved the desired outcome, compared with 34% of patients taking placebo…